Dow Jones Top Company Headlines at 5 PM ET: Apple Unveiled the New Siri AI. Here Are the Key Takeaways. | Amazon ...

Dow Jones
06/09

Apple Unveiled the New Siri AI. Here Are the Key Takeaways.

Apple showed off a new version of its Siri chatbot, technology developed with Google that the iPhone maker hopes will help power a comeback in AI.

----

Amazon Enters Agreement With Corning for Optical Fiber for Data Centers

Amazon.com said it entered a multibillion-dollar agreement with Corning to get optical fiber, cable and connectivity solutions to support its growing data center footprint.

----

Campbell's Sales Fall on Continued Weak Demand for Snacks

Campbell's sales fell in the fiscal third quarter, driven in part by further declines in its snacks business, but said its profit rose.

----

Vail Resorts Cuts Outlook Again as Weather Weighs on Visits

The ski-resort operator said weather conditions remained extremely unfavorable during the recent quarter, weighing on visits and revenue, particularly at Vail's resorts in the Rockies.

----

Nvidia Strikes Deals With Korean Tech Titans for AI Infrastructure Buildout

Nvidia is teaming up with leading South Korean technology companies to build large-scale artificial-intelligence infrastructure in Asia, seeking to solidify its data-center footprint and expand its AI ecosystem.

----

Intesa Bids $35 Billion for Monte dei Paschi

The approaches pit Intesa and BPM against each other for control of their domestic rival, continuing a wave of dealmaking activity in Italy's banking industry.

----

Johnson & Johnson to Buy Firefly Bio for $1 Billion

Johnson & Johnson has agreed to buy biotechnology company Firefly Bio for $1 billion in cash in a deal that bolsters the drugmaker's oncology pipeline.

----

Honeywell Backs Full-Year Guidance

Honeywell backed its full-year guidance as it looks to close a spinoff of its aerospace division.

----

Ingredion to Take Over Tate & Lyle in $3.6 Billion Deal

Ingredion offered the equivalent of $7.94 for each Tate & Lyle share, a 59% premium to the last closing price before takeover talks were disclosed last month.

----

Incyte to Buy Vega Therapeutics For Up to $2 Billion

Incyte has agreed to buy Vega Therapeutics for up to $2 billion in a deal that expands the biopharmaceutical company's hematology portfolio into bleeding disorders.

----

GoHealth Files for Bankruptcy, Handing Control to Lenders

The insurance brokerage, once valued at $6.6 billion, entered chapter 11 with nearly $1 billion in debt and a plan that leaves operations intact.

----

Wix.com Slashes 20% of Staff, Lowers Outlook as Restructuring Continues

The website-building and web-services platform said that it is scaling back parts of its business as part of a broader organizational realignment, moves that are expected to weigh on bookings and revenue growth in 2026.

----

FuelCell Earnings: Wider Loss, Higher Stock

FuelCell Energy stock has more than doubled in 2026 as the data-center buildout fuels demand for the company's fuel cell power plants.

----

Eli Lilly Shares Rise Premarket on Late-Stage Weight Loss Trial Success

A late-stage trial showed retatrutide was effective in weight loss and in alleviating obesity-linked conditions.

----

Novo Nordisk Weight-Loss Pill Prescriptions Hit Three Million Since Launch

The Danish drugmaker said the pill hit one million prescriptions 12 weeks after reaching U.S. pharmacies and online providers, and reached a further two million prescriptions in the following 10 weeks.

----

Roche Licenses Nurix Therapeutics Blood-Cancer Drug for Up to $2.3 Billion

The Swiss drugmaker said it would pay Nurix $700 million upfront, while development costs would be split 60-40, with Roche taking the larger share.

 

(END) Dow Jones Newswires

June 08, 2026 17:00 ET (21:00 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10